Cyy-272

Overview

Cyy-272 is an orally active JNK inhibitor with IC 50 values of 1.25 μM for JNK1 , 1.07 μM for JNK2 , and 1.24 μM for JNK3 . Cyy-272 exerts anti-inflammatory effects by inhibiting JNK phosphorylation, thereby alleviating acute lung injury (ALI) induced by lipopolysaccharide (LPS, HY-D1056). Additionally, Cyy-272 significantly reduces inflammation in cardiomyocytes and cardiac tissue induced by high lipid concentrations, further mitigating cardiac hypertrophy, fibrosis, and apoptosis . Cyy-272 can be used in the study of obese cardiomyopathy.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > JNK | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-169052
• CAS No.: 2644673-01-6
• Molecular Formula: C23H23F2N7
• Molecular Weight: 435.47
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source